Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge Letters Corresponding Author: Charles L. Loprinzi, MD, Mayo Clinic, 200 First St SW, Shu-Yue Zheng, MD Rochester, MN 55905 (cloprinzi@mayo.edu). Hua Duan, MD Published Online: September 17, 2020. doi:10.1001/jamaoncol.2020.3706 Hui-Juan Cui, PhD Conflict of Interest Disclosures: Dr Loprinzi reported receiving grants from the National Cancer Institute and personal fees from PledPharma, Disarm Author Affiliations: Graduate School, Beijing University of Chinese Medicine, Therapeutics, Asahi Kasei, Metys Pharmaceuticals, NKMax, Novartis, OnQuality Beijing, China (Zheng, Duan); Department of Integrative Oncology, China-Japan Pharmaceuticals, and Mitsubishi Tanabe Pharma. Dr Le-Rademacher reported Friendship Hospital, Beijing, China (Zheng, Cui). receiving grants from Mayo Clinic during the conduct of the study. No other Corresponding Author: Hui-Juan Cui, PhD, China-Japan Friendship Hospital, 2 disclosures were reported. Yinghua Dongjie, Hepingli, Beijing 100029, People’s Republic of China 1. Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the (chjzryhyy@sina.com). treatment of advanced cancer–related chronic nausea and/or vomiting: Published Online: September 24, 2020. doi:10.1001/jamaoncol.2020.3946 a randomized pilot trial. JAMA Oncol. 2020;6(6):1-5. doi:10.1001/jamaoncol. Conflict Interest Disclosures: None reported. 2020.1052 Funding/Support: This work was supported by Capital’s Funds for Health 2. Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in Improvement and Research (No. 2018-2-4065), National Natural Science http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge

JAMA Oncology , Volume 6 (11) – Nov 24, 2020

Loading next page...
 
/lp/american-medical-association/recurrence-of-immune-related-adverse-events-after-immune-checkpoint-vKuCEIDKh3
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.3955
Publisher site
See Article on Publisher Site

Abstract

Letters Corresponding Author: Charles L. Loprinzi, MD, Mayo Clinic, 200 First St SW, Shu-Yue Zheng, MD Rochester, MN 55905 (cloprinzi@mayo.edu). Hua Duan, MD Published Online: September 17, 2020. doi:10.1001/jamaoncol.2020.3706 Hui-Juan Cui, PhD Conflict of Interest Disclosures: Dr Loprinzi reported receiving grants from the National Cancer Institute and personal fees from PledPharma, Disarm Author Affiliations: Graduate School, Beijing University of Chinese Medicine, Therapeutics, Asahi Kasei, Metys Pharmaceuticals, NKMax, Novartis, OnQuality Beijing, China (Zheng, Duan); Department of Integrative Oncology, China-Japan Pharmaceuticals, and Mitsubishi Tanabe Pharma. Dr Le-Rademacher reported Friendship Hospital, Beijing, China (Zheng, Cui). receiving grants from Mayo Clinic during the conduct of the study. No other Corresponding Author: Hui-Juan Cui, PhD, China-Japan Friendship Hospital, 2 disclosures were reported. Yinghua Dongjie, Hepingli, Beijing 100029, People’s Republic of China 1. Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the (chjzryhyy@sina.com). treatment of advanced cancer–related chronic nausea and/or vomiting: Published Online: September 24, 2020. doi:10.1001/jamaoncol.2020.3946 a randomized pilot trial. JAMA Oncol. 2020;6(6):1-5. doi:10.1001/jamaoncol. Conflict Interest Disclosures: None reported. 2020.1052 Funding/Support: This work was supported by Capital’s Funds for Health 2. Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in Improvement and Research (No. 2018-2-4065), National Natural Science

Journal

JAMA OncologyAmerican Medical Association

Published: Nov 24, 2020

References